Siamak Daneshmand, MD

Siamak Daneshmand, MD

Scientific Advisory Board, Vesica Health

Dr. Daneshmand serves on the AUA Guideline panel for non-muscle invasive bladder cancer, as well as the AUA Guidelines panel for Testicular cancer. He currently serves as the chair of bladder section of the SUO Clinical Trials Consortium (SUO-CTC), is on the scientific steering committee of several bladder cancer clinical trials and has led over a dozen clinical trials in bladder cancer and a pivotal investigator-initiated multi-institutional trial in testicular cancer (SEMS). He is the current Secretary of the Western Section of the AUA. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 13 consecutive years.  He has been a career leader in academic investigations in bladder cancer and germ cell tumors and was recently appointed as the chair of the SWOG local bladder committee. He has been a visiting professor at more than 25 institutions around the world. He has presented over 500 abstracts at scientific meetings and has authored or co-authored over 400 peer-reviewed articles, reviews, and book chapters.

Dr. Daneshmand’s main clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy and post-chemo RPLND, the use of serum and molecular markers and new technologies in the diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion.